Guiyang Xintian Pharmaceutical Co.,Ltd. (SHE:002873)
China · Delayed Price · Currency is CNY 7.59
-0.10 (-1.30%)
Nov 6, 2026, 11:15 AM CST
SHE:002873 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 694.58 | 749.72 | 857.55 | 953.98 | 1,088 | 969.84 |
Revenue Growth | -8.04% | -12.57% | -10.11% | -12.29% | 12.15% | 29.15% |
Gross Profit Gross Profit Growth | 499.55 | 533.05 | 626.83 | 734.59 | 840.02 | 768.69 |
Operating Income Operating Income Growth | 21.62 | 22.86 | 58.11 | 97.17 | 130.75 | 126.58 |
Net Income Net Income Growth | 9.64 | 9.11 | 52.32 | 80.87 | 111.52 | 100.61 |
Earnings Per Share EPS Growth | 0.04 | 0.04 | 0.24 | 0.33 | 0.46 | 0.41 |
EPS Growth | 28.84% | -83.70% | -28.18% | -27.78% | 11.30% | 33.96% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 196.37 | 173.82 | 118.28 | 138.33 | 100.78 | 152.48 |
Total Debt Total Debt Growth | 547.95 | 668.9 | 560.18 | 602.01 | 486.17 | 429.79 |
Net Cash (Debt) Net Cash Growth | -351.58 | -495.09 | -441.9 | -463.68 | -385.39 | -277.31 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1.53 | -2.10 | -2.01 | -1.90 | -1.58 | -1.13 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 143.86 | 83.73 | 88.13 | 77.78 | 75.82 | 124.3 |
Capital Expenditures CapEx Growth | -65.62 | -51.59 | -61.45 | -101.7 | -129.2 | -105.69 |
Free Cash Flow Free Cash Flow Growth | 78.24 | 32.14 | 26.68 | -23.92 | -53.38 | 18.61 |
Free Cash Flow Growth | -27.55% | 20.48% | - | - | - | -82.71% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 71.92% | 71.10% | 73.10% | 77.00% | 77.23% | 79.26% |
Operating Margin | 3.11% | 3.05% | 6.78% | 10.19% | 12.02% | 13.05% |
Pretax Margin | 1.58% | 1.30% | 7.08% | 9.69% | 11.16% | 12.03% |
Profit Margin | 1.39% | 1.21% | 6.10% | 8.48% | 10.25% | 10.37% |
FCF Margin | 11.27% | 4.29% | 3.11% | -2.51% | -4.91% | 1.92% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.030 | 0.030 | 0.100 | 0.070 | 0.100 | 0.086 |
Dividend Per Share Growth | -70.00% | -70.00% | 42.86% | -30.00% | 16.69% | 40.03% |
Dividend Yield | 0.40% | 0.30% | 1.07% | 0.56% | 0.69% | 0.61% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 180.86 | 256.18 | 41.86 | 35.46 | 29.94 | 32.04 |
Forward PE | - | 23.52 | 23.52 | 18.74 | 20.49 | - |
P/FCF Ratio | 23.06 | 72.62 | 82.10 | - | - | 173.24 |
PS Ratio | 2.60 | 3.11 | 2.55 | 3.01 | 3.07 | 3.32 |